{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:18:28Z","timestamp":1791397108621,"version":"4.3.3"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Soonchunhyang University Research Fund"},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2022R1A2C3005586"],"award-info":[{"award-number":["2022R1A2C3005586"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>While clinical RCTs have clearly evidenced that the use of androgen receptor pathway inhibitor (ARPI)s for patients with advanced prostate cancer, can significantly delay disease progression, there is insufficient evidence on their safety profiles to warrant their unqualified implementation as the treatment of choice or with which to choose between them. We aim to provide more substantial evidence for adverse event (AE)s of ARPI by analyzing real-world data (RWD) to select optimal ARPI for individual treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We used data from the Food and Drug Administration Adverse Event Reporting System (FAERS) in the US, between April 30, 2014 and April 30, 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We estimated proportional risk ratio (PRR)s of AEs in the US. We also compared the likelihood of AEs by age, reporter type, and ARPI groups: 1) Group 1, Enzalutamide with other medications; 2) Group 2, Apalutamide with other medications; 3) Group 3, Darolutamide with other medications; 4) Group 4, Abiraterone with other medications; 5) Group 5, Abiraterone\u2009+\u2009Enzalutamide with other medications. We identified 107,582 AEs among 44,856 US residents who were treated with ARPIs for prostate cancer. By ARPI groups, the AE of GI was the highest in Group 1 and Group 3, and the AE of vascular was the highest in Group 4 and Group 5. In particular, Group 2 showed very statistically significantly higher levels of PRR 3.558 (95%CI: 3.489\u20133.627) of skin-related AE compared to other groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study provides important insight that we analyzed RWD and evaluated comparative drug safety across all type of prostate cancer. Although we could not make a conclusion whether which is the safest ARPI, we can suggest that each ARPIs have different types of AEs hence we can use this information during choosing ARPIs for prostate cancer patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0335459","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T17:32:28Z","timestamp":1761327148000},"page":"e0335459","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Adverse events of androgen receptor pathway inhibitors in prostate cancer from real world data"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9984-1138","authenticated-orcid":true,"given":"Jongsoo","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6478-0902","authenticated-orcid":true,"given":"Subeen","family":"Leem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-Yeup","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin I.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4143-7383","authenticated-orcid":true,"given":"Sung Ryul","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4490-3610","authenticated-orcid":true,"given":"Jae Heon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"pone.0335459.ref001","unstructured":"National Cancer Institute. Cancer stat facts: prostate cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html. 2024. Accessed 2024 June 9."},{"key":"pone.0335459.ref002","doi-asserted-by":"crossref","first-page":"811044","DOI":"10.3389\/fpubh.2022.811044","article-title":"Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019","volume":"10","author":"L Wang","year":"2022","journal-title":"Front Public Health"},{"issue":"1","key":"pone.0335459.ref003","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41391-018-0078-1","article-title":"Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies","volume":"22","author":"SIR Alpajaro","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"pone.0335459.ref004","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.mcna.2017.11.001","article-title":"Prostate Cancer Screening","volume":"102","author":"WJ Catalona","year":"2018","journal-title":"Med Clin North Am"},{"issue":"41","key":"pone.0335459.ref005","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate Cancer Incidence and Survival, by Stage and Race\/Ethnicity - United States, 2001-2017","volume":"69","author":"DA Siegel","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"pone.0335459.ref006","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMra1701695","article-title":"Metastatic Prostate Cancer","volume":"378","author":"O Sartor","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0335459.ref007","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.prnil.2023.12.002","article-title":"Real-world effects of novel androgen receptor axis-targeted agents on oncological outcomes in non-metastatic castration-resistant prostate cancer: A multi-institutional retrospective study","volume":"12","author":"N Fujita","year":"2024","journal-title":"Prostate Int"},{"issue":"32","key":"pone.0335459.ref008","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer","volume":"37","author":"AJ Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"20","key":"pone.0335459.ref009","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study","volume":"39","author":"KN Chi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0335459.ref010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","volume":"381","author":"ID Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0335459.ref011","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14737140.2017.1333903","article-title":"Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment","volume":"17","author":"A Anantharaman","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"pone.0335459.ref012","doi-asserted-by":"crossref","first-page":"1179554919833927","DOI":"10.1177\/1179554919833927","article-title":"The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer","volume":"13","author":"J El-Amm","year":"2019","journal-title":"Clin Med Insights Oncol"},{"key":"pone.0335459.ref013","unstructured":"US Food and Drug Administration. FDA approves apalutamide for non-metastatic castration-resistant prostate cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-apalutamide-non-metastatic-castration-resistant-prostate-cancer. Accessed 2024 June 9."},{"key":"pone.0335459.ref014","unstructured":"US Food and Drug Administration. FDA approves darolutamide for non-metastatic castration-resistant prostate cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-darolutamide-non-metastatic-castration-resistant-prostate-cancer. Accessed 2024 June 9."},{"issue":"4","key":"pone.0335459.ref015","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/13696998.2019.1705313","article-title":"Real-world incidence and burden of adverse events among non-metastatic prostate cancer patients treated with secondary hormonal therapies following androgen deprivation therapy","volume":"23","author":"A Shah","year":"2020","journal-title":"J Med Econ"},{"issue":"2","key":"pone.0335459.ref016","first-page":"136","article-title":"A Systematic Review of the Effect of Cancer Treatment on Work Productivity of Patients and Caregivers","volume":"23","author":"KM Kamal","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"pone.0335459.ref017","doi-asserted-by":"crossref","first-page":"1176935119835522","DOI":"10.1177\/1176935119835522","article-title":"Transcriptomics Signature from Next-Generation Sequencing Data Reveals New Transcriptomic Biomarkers Related to Prostate Cancer","volume":"18","author":"A Alkhateeb","year":"2019","journal-title":"Cancer Inform"},{"issue":"9596","key":"pone.0335459.ref018","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"E von Elm","year":"2007","journal-title":"Lancet"},{"key":"pone.0335459.ref019","unstructured":"Office of the Federal Register and the Government Publishing Office. Electronic Code of Federal Regulations. https:\/\/www.ecfr.gov\/cgi-bin\/retrieveECFR?gp=&SID=83cd09e1c0f5c6937cd9d7513160fc3f&pitd=20180719&n=pt45.1.46&r=PART&ty=HTML#se45.1.46_1104. 2024. Accessed 2024 June 9."},{"key":"pone.0335459.ref020","unstructured":"US Food and Drug Administration. Questions and answers on FDA\u2019s Adverse Event Reporting System. https:\/\/www.fda.gov\/drugs\/surveillance\/fda-adverse-event-reporting-system-faers. 2024. Accessed 2024 June 9."},{"key":"pone.0335459.ref021","year":"2024"},{"key":"pone.0335459.ref022","unstructured":"Harmonisation for better health: MedDRA work products. http:\/\/www.ich.org\/products\/meddra.html. Accessed 2024 June 9."},{"key":"pone.0335459.ref023","unstructured":"US Food and Drug Administration. Data Mining at FDA White Paper. 2018. https:\/\/www.fda.gov\/science-research\/data-mining\/data-mining-fda-white-paper"},{"key":"pone.0335459.ref024","doi-asserted-by":"crossref","first-page":"1338862","DOI":"10.3389\/fpubh.2023.1338862","article-title":"Otorhinolaryngologic complications after COVID-19 vaccination, vaccine adverse event reporting system (VAERS)","volume":"11","author":"J Shin","year":"2024","journal-title":"Front Public Health"},{"key":"pone.0335459.ref025","unstructured":"B\u00f6hm R. Primer on disproportionality analysis. http:\/\/openvigil.sourceforge.net\/doc\/DPA.pdf. Accessed 2024 June 9."},{"issue":"6","key":"pone.0335459.ref026","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"SJ Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pone.0335459.ref027","doi-asserted-by":"crossref","DOI":"10.1177\/2042098619882819","article-title":"Evaluation of quantitative signal detection in EudraVigilance for orphan drugs: possible risk of false negatives","volume":"10","author":"M Sardella","year":"2019","journal-title":"Ther Adv Drug Saf"},{"issue":"3","key":"pone.0335459.ref028","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jamaoncol.2020.6973","article-title":"Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis","volume":"7","author":"L Wang","year":"2021","journal-title":"JAMA Oncol"},{"issue":"8","key":"pone.0335459.ref029","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/s41416-024-02823-3","article-title":"Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis","volume":"131","author":"T Wang","year":"2024","journal-title":"Br J Cancer"},{"issue":"3","key":"pone.0335459.ref030","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41391-023-00775-y","article-title":"Safety profile of darolutamide versus placebo: a systematic review and meta-analysis","volume":"27","author":"F Turco","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"pone.0335459.ref031","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/03008916221090323","article-title":"Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis","volume":"109","author":"M Santoni","year":"2023","journal-title":"Tumori"},{"issue":"2","key":"pone.0335459.ref032","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/JU.0000000000001767","article-title":"Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer","volume":"206","author":"S Halabi","year":"2021","journal-title":"J Urol"},{"issue":"4","key":"pone.0335459.ref033","first-page":"332","article-title":"Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer","volume":"21","author":"A Abbasi","year":"2021","journal-title":"Curr Mol Med"},{"key":"pone.0335459.ref034","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1200\/JCO.2019.37.7_suppl.156","article-title":"Higher blood\u2013brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography","volume":"37","author":"C Zurth","year":"2019","journal-title":"JCO"},{"issue":"5","key":"pone.0335459.ref035","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2019.07.001","article-title":"New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes","volume":"17","author":"V Di Nunno","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"pone.0335459.ref036","unstructured":"US Food and Drug Administration. Highlights of prescribing information: ERLEADA (apalutamide). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210951s001lbl.pdf. Accessed 2024 June 9."},{"key":"pone.0335459.ref037","unstructured":"US Food and Drug Administration. Highlights of prescribing information: XTANDI (enzalutamide). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203415lbl.pdf 2012. Accessed 2024 June 9."},{"issue":"5","key":"pone.0335459.ref038","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djaa134","article-title":"Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer","volume":"113","author":"JZ Drago","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"pone.0335459.ref039","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.euo.2023.01.001","article-title":"Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis","volume":"6","author":"B Cao","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"pone.0335459.ref040","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1007\/s10147-020-01777-9","article-title":"Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","volume":"25","author":"K Mori","year":"2020","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"pone.0335459.ref041","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41391-021-00395-4","article-title":"Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis","volume":"25","author":"M Wenzel","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"pone.0335459.ref042","doi-asserted-by":"crossref","first-page":"1131033","DOI":"10.3389\/fendo.2023.1131033","article-title":"The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis","volume":"14","author":"X Zhang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0340507","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000}}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0335459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T17:32:36Z","timestamp":1761327156000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0335459"}},"subtitle":[],"editor":[{"given":"Xing-Xiong","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":42,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0335459","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]}}}